Un potentiel encore significatif dans l’insuline - ACHAT - OC 87€ (vs 50€)
Dans le cadre de notre changement de couverture et suite à la publication des résultats cliniques de phase IIa d’Hinsbet, nous ajustons notre modèle de valorisation sur ADOCIA. Avec une augmentation de notre objectif à 87€ vs 50€ avant notre mise sous revue, nous maintenons notre recommandation à ACHAT sur la valeur. La société annonçait hier les résultats positifs d’Hinsbet en phase IIa, en réponse nous augmentons notre probabilité de succès du composé à 50% en considérant dans notre valorisation un accord de partenariat trouvé dès 2016.ADOCIA is a biotechnology company based in France. Co. specializes in the development of formulations for already-approved therapeutic proteins with a primary focus on insulins and treatments for diabetic foot ulcers. Co.'s biotherapy products are used in tissue regeneration and for treating chronic diseases. Co.'s proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins in areas such as wound Healing, diabetes, ulcers and monoclonal antibody creation. Co. also maintains activities in the formulation of monoclonal antibodies for the treatment of various chronic pathologies (oncology, inflammation, etc.).
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.